Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Iclusig Ponatinib Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Idhifa Enasidenib Acute myeloid leukemia (AML) Do not reimburse Complete
Ikervis cyclosporine keratitis, severe Withdrawn
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndrome Do not list Complete
Ilaris Canakinumab Systemic Juvenile Idiopathic Arthritis Reimburse with clinical criteria and/or conditions Complete
Ilumya tildrakizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn
Iluvien fluocinolone acetonide intravitreal implant diabetic macular edema Do not reimburse Complete
Imbruvica ibrutinib Chronic graft versus host disease Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica ibrutinib Chronic lymphocytic leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete